Researchers identified a small peptide which targets the androgen receptor (AR) and associated Filamin A (FlnA), which may impede the invasive phenotype of prostate cancer cells which lead to more aggressive disease. The findings were published in the journal Cells.
In this study, researchers used a low concentration of the AR-derived peptide Rh-2025u, which is known to interfere with the AR/FlnA association. Following analysis, they found that Rh-2025 has the potential to overcome the resistance to 2nd generation inhibitors by disrupting the downstream signaling of AR/FlnA.
The researchers wrote that “the current research aims to discover many targets which could be “druggable” for inhibiting invasiveness of PC cells. The stapled peptide here used could be placed in this area, but with an added value. By inhibiting the invasiveness of both PC and its surrounding cells, it stands as an excellent candidate in this field. By this approach, PC epithelial cells and their microenvironment could be evaluated and targeted not as two distinguished compartments, but as one. These findings try to address the need for a new generation of drugs for metastatic PC therapy.”